COM503
COM503 is a high-affinity anti-IL18BP human monoclonal antibody with a Kd value of 0.291 pM. COM503 binds to IL18BP, blocks the IL18BP:IL18 interaction, displaces IL18 from preformed complexes, and enhances the activation and function of T cells and NK cells. COM503 induces anti-tumor effects by relieving the activity inhibition of endogenous IL18 in the tumor microenvironment. COM503 can be used for cancer research. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL18BP 0.291 pM (Kd) |
IL-18 |
In Vitro
COM503 binds to purified human IL18BP with high affinity (Kd = 0.291 pM), which is higher than the affinity between endogenous human IL18 and IL18BP (Kd = 0.441 pM)[1].
COM503 (1.25-10 μg/mL; 1 h (complex incubation at 37°C); RT or 37°C (assay incubation steps)) displaces IL18 from preformed recombinant human IL18:IL18BP complexes in a dose-dependent manner in vitro, with an EC50 of 14 nM[1].
COM503 (24 h) restores the activation of human melanoma CD8+ tumor-infiltrating lymphocytes (TILs) co-cultured with MEL624 cells and mediated by IL18, and increases the secretion levels of IFN-γ and TNF-α as well as the expression of CD137 in CD8+ TILs[1].
COM503 (24 h) restores IL18-mediated activation of isolated human NK cells blocked by preformed IL18:IL18BP complexes, and increases IFN-γ secretion levels[1].
COM503 (10 μg/mL; 24 h) restores IL18-mediated activation of CMV-reactive CD8+ T cells co-cultured with PD-L1-overexpressing MEL624 cells[1].
COM503 (24 h) restores IL18-mediated activation of human peripheral blood mononuclear cells (PBMCs) by blocking endogenously secreted IL18BP, and increases IFN-γ secretion levels with a mean EC50 of 1.6 nM[1].
COM503 (20 μg/mL; 24 h) enhances IFN-γ secretion by human melanoma CD8+ tumor-infiltrating lymphocytes (TILs) co-cultured with MEL624 cells through blocking endogenously secreted IL18BP at physiologically relevant IL18 concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Gene ID
Accession
O95998
Target
IL-18BP
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
신청
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Multiplex immunofluorescence IHC
Multiplex immunofluorescence IHC detects multiple protein biomarkers in one tissue section by sequential antibody staining, HRP-mediated tyramide fluorophore deposition, heat-mediated antibody stripping, nuclear counterstaining, multispectral imaging, spectral unmixing, and digital cell phenotyping; TSA deposits fluorophore near the antigen so the fluorescence signal remains after primary and secondary antibodies are removed, enabling repeated staining cycles, including with antibodies from the same host species. Classic FFPE tumor immune-profiling applications use panels such as CD3, CD8, CD68/CD163, FOXP3, PD-1, PD-L1, pancytokeratin, Ki67, and DAPI to identify tumor cells, immune-cell subsets, checkpoint-marker expression, co-expression phenotypes, cell density, and spatial relationships in the tumor microenvironment.
-
Multiplex immunohistochemistry
Multiplex immunohistochemistry (mIHC), also known as tyramide dignal amplification (TSA), is an enzymatic detection method that uses horseradish peroxidase (HRP) to perform high-density in-situ labeling of target proteins or nucleic acids.
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)